USA - engelsk - NLM (National Library of Medicine)

abbvie - daclizumab (unii: cuj2mvi71y) (daclizumab - unii:cuj2mvi71y) - daclizumab 150 mg in 1 ml - zinbryta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (ms). because of its safety profile, the use of zinbryta should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of ms. zinbryta is contraindicated in patients with: - pre-existing hepatic disease or hepatic impairment, including alt or ast at least 2 times the uln, because zinbryta could exacerbate existing liver dysfunction [see dosage and administration (2.3) and warnings and precautions (5.1)] . - a history of autoimmune hepatitis or other autoimmune condition involving the liver [see warnings and precautions (5.1)]. - a history of hypersensitivity to daclizumab or any other components of the formulation. use in such patients may result in anaphylaxis or life-threatening multi-organ hypersensitivity [see warnings and precautions (5.4)] . risk summary there are no adequate data on the developmental risk associated with use of zinbryta in

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

biogen australia pty ltd - daclizumab -

Sveits - tysk - Swissmedic (Swiss Agency for Therapeutic Products)

biogen switzerland ag - daclizumabum beta - injektionslösung in einer fertigspritze - daclizumabum beta 150 mg, dinatrii succinas, acidum succinicum, natrii chloridum, polysorbatum 80, aqua ad iniectabilia q.s. ad solutionem pro 1 ml. - multiple sklerose - biotechnologika

Sveits - tysk - Swissmedic (Swiss Agency for Therapeutic Products)

biogen switzerland ag - daclizumabum beta - injektionslösung in einem fertigpen - daclizumabum beta 150 mg, dinatrii succinas, acidum succinicum, natrii chloridum, polysorbatum 80, aqua ad iniectabilia q.s. ad solutionem pro 1 ml. - multiple sklerose - biotechnologika

Den europeiske union - italiensk - EMA (European Medicines Agency)

biogen idec ltd - daclizumab - sclerosi multipla - immunosoppressori - zinbryta è indicato nei pazienti adulti per il trattamento di forme recidivanti di sclerosi multipla (rms).

Den europeiske union - dansk - EMA (European Medicines Agency)

biogen idec ltd - daclizumab - multipel sclerose - immunosuppressiva - zinbryta er indiceret hos voksne patienter til behandling af recidiverende former for multipel sklerose (rms).

Den europeiske union - rumensk - EMA (European Medicines Agency)

roche registration ltd. - daclizumab - graft rejection; kidney transplantation - imunosupresoare - zenapax este indicat pentru profilaxia de respingere acută de organe în de novo transplantul grefei renale şi urmează să fie utilizat concomitent cu un regim de imunosupresoare, inclusiv ciclosporina si corticosteroizii la pacienţii care nu sunt imunizate extrem.

Den europeiske union - tysk - EMA (European Medicines Agency)

biogen idec ltd - daclizumab - multiple sklerose - immunsuppressiva - zinbryta ist bei erwachsenen patienten zur behandlung von schubförmig verlaufenden formen der multiplen sklerose (rms) indiziert..

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

biogen australia pty ltd - daclizumab -

Sveits - fransk - Swissmedic (Swiss Agency for Therapeutic Products)

biogen switzerland ag - daclizumabum beta - injektionslösung in einer fertigspritze - daclizumabum beta 150 mg, dinatrii succinas, acidum succinicum, natrii chloridum, polysorbatum 80, aqua ad iniectabilia q.s. ad solutionem pro 1 ml. - multiple sklerose - biotechnologika